Now showing items 1-2 of 2

    • Cooperation of imipramine blue and tyrosine kinase blockade demonstrates activity against chronic myeloid leukemia 

      Laidlaw, Kamilla M.E.; Berhan, Samuel; Liu, Suhu; Silvestri, Giovannino; Holyoake, Tessa L.; Frank, David A.; Aggarwal, Bharat; Bonner, Michael Y.; Perrotti, Danilo; Jørgensen, Heather G.; Arbiser, Jack L. (Impact Journals LLC, 2016)
      The use of tyrosine kinase inhibitors (TKI), including nilotinib, has revolutionized the treatment of chronic myeloid leukemia (CML). However current unmet clinical needs include combating activation of additional survival ...
    • Detecting T-cell Reactivity to Whole Cell Vaccines 

      Brusic, Ana; Hainz, Ursula; Wadleigh, Martha; Neuberg, Donna; Su, Mei; Canning, Christine M.; DeAngelo, Daniel J.; Stone, Richard M.; Lee, Jeng-Shin; Mulligan, Richard C.; Ritz, Jerome; Dranoff, Glenn; Sasada, Tetsuro; Wu, Catherine J. (Landes Bioscience, 2012)
      BCR-ABL\(^+\) K562 cells hold clinical promise as a component of cancer vaccines, either as bystander cells genetically modified to express immunostimulatory molecules, or as a source of leukemia antigens. To develop a ...